Days of Medicine shares: issued a private issue of stock plan

Event: The company intends to include the holding shareholder pharmaceutical group, not more than 10 of specific investors in the number of non-public offerings of shares, not more than 66.5 million shares, the issue price is not less than 8.27 yuan/share, the total amount of fund-raising not more than 550 million yuan.　　To raise funds to invest in three aspects, one: the acquisition of Tian ' an pharmaceutical amino acid raw materials business and related assets and liabilities; second: The acquisition of Jin Yao Biological sewage treatment of environmental engineering assets; Third: Corticosteroids for the upgrading of raw materials and expansion of production projects.　　Pure Light Analysis: 1. The company's main business is the manufacture and operation of chemical raw materials, Chinese and western pharmaceutical products, Chinese herbal medicine and Traditional Chinese medicine processing, pharmaceutical intermediates, chemical raw materials, cosmetics, biodiesel and related technologies and raw materials processing. 2. Raise funds to a: acquisition of the pharmaceutical industry owned amino acid pharmaceutical business and related assets and liabilities.　　Through this acquisition, the company will integrate the holding shareholder pharmaceutical group's raw material assets, to achieve the overall API business listing. 3. Raise funds to two: acquisition of assets Jin Yao Bio-owned sewage treatment environmental engineering assets.　　Through this acquisition, the company will have an independent, complete sewage treatment facilities, can reduce related transactions, save the company's environmental costs, improve the company's environmental level. 4. Raise funds to three: the company's existing corticosteroid raw materials business technology upgrading and capacity expansion project. After the implementation of the project, the company will add 210 tons of corticosteroid raw materials intermediates capacity (100 tons of bio-dehydrogenation intermediates and 110 tons of bio-oxide intermediates), the use of new synthetic technology to add 5 tons of acetic acid hydrogenated cortisone raw materials, 5 tons of methyl-poured nylon series of raw drugs,　　15 tons of Prednisolone series of raw materials and 5 tons of betamethasone products of the production capacity of raw materials. 5. Regardless of the impact of this non-public offering on the company's future performance, the company's current stock price is 60x,46x,37x to the 2010-2012 P/E ratio, with a higher valuation.